BMAL1 and cancer: Consistent with previous studies reporting lowered Bmal1 expression upon SR9009 exposure [76,77], we showed a dose-dependent reduction in Bmal1 mRNA after 12 and 24 h SR9009 exposure in the absence of cytokines, using concentrations adapted from a recent study in cancer cell lines [78], hereby proving the anticipated biological activity of the agonist.